Loading...
Header Logo
Keywords
Last Name
Institution

MARLA HAWKINS DAVES

TitleAssistant Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Pediatrics
DivisionPediatrics-Hem-Onc Clinical Div
Address6621 FANNIN, SUITE 1410.00
HOUSTON TX 77030
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Featured Presentations

    Collapse Overview 
    Collapse overview
    Dr. Marla Daves is a board certified pediatric hematologist/oncologist, as well as a board certified clinical informaticist. Clinically, she specializes in pediatric leukemia. She is also the Texas Children's Cancer Center Director of Epic. She helped lead the implementation of the Beacon, the Epic oncology module and leads ongoing maintenance. She is currently working to apply informatics tools to improve healthcare quality and clinical research processes. She is also involved in the development of clinical research databases to improve the secondary use of clinical data for research.

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Miller TP, Li Y, Kavcic M, Getz KD, Huang YV, Sung L, Alonzo TA, Gerbing R, Daves MH, Horton TM, Pulsipher MA, Pollard J, Bagatell R, Seif AE, Fisher BT, Luger S, Gamis AS, Adamson PC, Aplenc R. Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Haematologica. 2017 09; 102(9):e340-e343. PMID: 28642300.
      View in: PubMed
    2. Miller TP, Li Y, Kavcic M, Troxel AB, Huang YS, Sung L, Alonzo TA, Gerbing R, Hall M, Daves MH, Horton TM, Pulsipher MA, Pollard JA, Bagatell R, Seif AE, Fisher BT, Luger S, Gamis AS, Adamson PC, Aplenc R. Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. J Clin Oncol. 2016 05 01; 34(13):1537-43. PMID: 26884558.
      View in: PubMed
    3. Miller TP, Getz KD, Kavcic M, Li Y, Huang YS, Sung L, Alonzo TA, Gerbing R, Daves M, Horton TM, Pulsipher MA, Pollard J, Bagatell R, Seif AE, Fisher BT, Gamis AS, Aplenc R. A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group. Leuk Lymphoma. 2016 07; 57(7):1567-74. PMID: 26727639.
      View in: PubMed
    4. Nickel RS, Daves M, Keller F. Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib. Pediatr Blood Cancer. 2015 Nov; 62(11):2050-1. PMID: 25939962.
      View in: PubMed
    5. Nickel RS, Keller F, Bergsagel J, Cooper T, Daves M, Sabnis H, Lew G. Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma. Pediatr Blood Cancer. 2014 May; 61(5):810-4. PMID: 24357218; PMCID: PMC4317248.
    6. Hockenberry MJ, McCarthy KS, Taylor OA, Hesselgrave J, Bernhardt MB, Daves M, Kamdar K. Using improvement science to promote evidence-based practice in a childhood cancer and hematology center. J Pediatr Oncol Nurs. 2012 Jan-Feb; 29(1):5-13. PMID: 22367765.
      View in: PubMed
    7. Daves MH, Hilsenbeck SG, Lau CC, Man TK. Meta-analysis of multiple microarray datasets reveals a common gene signature of metastasis in solid tumors. BMC Med Genomics. 2011 Jul 07; 4:56. PMID: 21736749; PMCID: PMC3212952.
    DAVES's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description